Evidence map›Paper›PMID 26207366›Full record

ArticlePloS one2015

Botulinum Neurotoxins Can Enter Cultured Neurons Independent of Synaptic Vesicle Recycling.

Sabine Pellett, William H Tepp, Jacob M Scherf, Eric A Johnson

Open access · goldAbstract readComparative Study
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 21 citations in OpenAlex.

  1. The Use of Botulinum Toxin in the Management of Headache Disorders.Handbook of experimental pharmacology · 2021
    Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Gangliosides interact with synaptotagmin to form the high-affinity receptor complex for botulinum neurotoxin B.Proceedings of the National Academy of Sciences of the United States of America · 2019
    Article
  7. Review
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Sabine PellettDepartment of Bacteriology, University of Wisconsin-Madison, Madison, Wisconsin, 53706, United States of America.
William H TeppDepartment of Bacteriology, University of Wisconsin-Madison, Madison, Wisconsin, 53706, United States of America.
Jacob M ScherfDepartment of Bacteriology, University of Wisconsin-Madison, Madison, Wisconsin, 53706, United States of America.
Eric A JohnsonDepartment of Bacteriology, University of Wisconsin-Madison, Madison, Wisconsin, 53706, United States of America.
University of Wisconsin–Madison · US

Funding

Novel therapeutic approaches to treatment of botulinum neurotoxin poisoning.R01AI093504 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Konstantin Ichtchenko · 2011 to 2026
$13.9M
NIAID NIH HHS R01 AI093504
6 · The paper itself

Abstract

Botulinum neurotoxins (BoNTs) are the causative agent of the severe and long-lasting disease botulism. At least seven different serotypes of BoNTs (denoted A-G) have been described. All BoNTs enter human or animal neuronal cells via receptor mediated endocytosis and cleave cytosolic SNARE proteins, resulting in a block of synaptic vesicle exocytosis, leading to the flaccid paralysis characteristic of botulism. Previous data have indicated that once a neuronal cell has been intoxicated by a BoNT, further entry of the same or other BoNTs is prevented due to disruption of synaptic vesicle recycling. However, it has also been shown that cultured neurons exposed to BoNT/A are still capable of taking up BoNT/E. In this report we show that in general BoNTs can enter cultured human or mouse neuronal cells that have previously been intoxicated with another BoNT serotype. Quantitative analysis of cell entry by assessing SNARE cleavage revealed none or only a minor difference in the efficiency of uptake of BoNTs into previously intoxicated neurons. Examination of the endocytic entry pathway by specific endocytosis inhibitors indicated that BoNTs are taken up by clathrin coated pits in both non pre-exposed and pre-exposed neurons. LDH release assays indicated that hiPSC derived neurons exposed consecutively to two different BoNT serotypes remained viable and healthy except in the case of BoNT/E or combinations of BoNT/E with BoNT/B, /D, or /F. Overall, our data indicate that previous intoxication of neuronal cells with BoNT does not inhibit further uptake of BoNTs.

Indexed as

AnimalsBiological AssayBiological TransportBotulinum ToxinsBotulismCells, CulturedEndocytosisHumansInduced Pluripotent Stem CellsInjections, IntraperitonealLethal Dose 50MiceMice, Inbred ICRNeurogenesisNeuronsSerotypingBotulinum ToxinsSNAP25 protein, humanSynaptosomal-Associated Protein 25VAMP2 protein, humanVesicle-Associated Membrane Protein 2

Identifiers

PMID26207366
PMCPMC4514655
OpenAlexW943869171

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.